FDA approves rapid MRSA/MSSA test

Share this article:

The U.S. Food and Drug Administration has approved a blood culture test that can determine if Staphylococcus aureus bacteria infections are methicillin resistant (MRSA) or methicillin susceptible (MSSA).

The KeyPath MRSA/MSSA Blood Culture Test, which does not require any specific instruments aside from blood culture equipment, can distinguish between the diseases within approximately five hours after any bacterial growth is first detected in a sample, the FDA said. The distinction between MSSA and MRSA is important: Some MSSA infections can be treated using certain antibiotics, whereas MRSA infections are resistant to most antibiotics.

This is good news for nursing homes and hospitals, where infections among patients with weakened immune systems can be deadly and spread rapidly.

“Clearing this test gives healthcare professionals a test that can confirm S. aureus and then identify whether the bacteria is MRSA or MSSA,” said Alberto Gutierrez, Ph.D., director of the Office of In Vitro Diagnostics Device Evaluation and Safety in the FDA's Center for Devices and Radiological Health. “This not only saves time in diagnosing potentially life-threatening infections but also allows healthcare professionals to optimize treatment and start appropriate contact precautions to prevent the spread of the organism.”
Share this article:

More in News

Large hepatitis outbreak reaches 47 cases, podiatry company denies ManorCare's charges

The number of people infected in an infamous North Dakota Hepatitis C outbreak has risen, state health officials say.

National Quality Forum supports quality measures in bill to standardize post-acute assessments

National Quality Forum supports quality measures in bill ...

The National Quality Forum has come out in strong support of a proposed standardized quality measures, such as skin integrity, across different types of post-acute care settings. Uniform assessments are ...

CMS changes mind on hospice drugs

The Centers for Medicaid & Medicare Services has revised guidance on authorization of hospice drugs for those under Medicare Advantage and Part D plans, according to a new memo.